Prognostic significance of metallothionein in B-cell lymphomas

Blood

Volumn 108, Issue 10, 2006, Pages 3514-3519

  Poulsen, Christian Bjørn ^a   Borup, Rehannah ^b   Borregaard, Niels ^b   Nielsen, Finn Cilius ^b   Møller, Michael Boe ^b   Ralfkiaer, Elisabeth ^b  

^a Rigshospitalet   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; METALLOTHIONEIN I; METALLOTHIONEIN II;

ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; LYMPHOMA CELL; MACROPHAGE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REMISSION; RISK FACTOR; SURVIVAL RATE; TREATMENT FAILURE; UPREGULATION;

EID: 33751194655     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-04-015305     Document Type: Article

References (39)

1. Vasak M. Advances in metallothionein structure and functions. J Trace Elem Med Biol. 2005;19:13-17.
2. Vasak M, Hasler DW. Metallothioneins: new functional and structural insights. Curr Opin Chem Biol. 2000;4:177-183.
3. Coyle P, Philcox JC, Carey LC, Rofe AM. Metallothionein: the multipurpose protein. Cell Mol Life Sci. 2002;59:627-647.
4. Searle PF, Davison BL, Stuart GW, et al. Regulation, linkage, and sequence of mouse metallothionein I and II genes. Mol Cell Biol. 1984;4:1221-1230.
5. Theocharis SE, Margeli AP, Klijanienko JT, Kouraklis GP. Metallothionein expression in human neoplasia. Histopathology. 2004;45:103-118.
6. Chimienti F, Aouffen M, Favier A, Seve M. Zinc homeostasis-regulating proteins: new drug targets for triggering cell fate. Curr Drug Targets. 2003;4:323-338.
7. Jayasurya A, Bay BH, Yap WM, Tan NG. Infiltrating lymphocytes in undifferentiated nasopharyngeal cancer lack metallothionein expression. Cancer Lett. 2000;155:99-104.
8. Cherian MG, Jayasurya A, Bay BH. Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res. 2003;533:201-209.
9. Surowiak P, Paluchowski P, Dziegiel P, et al. Lack of relationship between metallothionein (MT) expression and proliferation exponents in cells of primary ductal breast cancer of G2 grade of differentiation. Med Sci Monit. 2004;10:BR300-BR305.
10. Weinlich G, Eisendle K, Hassler E, et al. Metallothionein: overexpression as a highly significant prognostic factor in melanoma: a prospective study on 1270 patients. Br J Cancer. 2006;27:835-841.
11. Mitropoulos D, Kyroudi-Voulgari A, Theocharis S, et al. Prognostic significance of metallothionein expression in renal cell carcinoma. World J Surg Oncol. 2005;3:5.
12. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
13. Jasani B, Elmes ME. Immunohistochemical detection of metallothionein. Methods Enzymol. 1991;205:95-107.
14. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A. 2001;98:31-36.
15. Poulsen CB, Borup R, Nielsen FC, et al. Microarray-based classification of diffuse large B-cell lymphoma. Eur J Haematol. 2005;74:453-465.
16. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-1947.
17. Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005;105:1851-1861.
18. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511.
19. Rosenwald A, Staudt LM. Gene expression profiling of diffuse large B-cell lymphoma. Leuk Lymphoma. 2003;44(suppl 3):S41-S47.
20. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8:68-74.
21. Volm M. Multidrug resistance and its reversal. Anticancer Res. 1998;18:2905-2917.
22. Palmiter RD. The elusive function of metallothioneins. Proc Natl Acad Sci U S A. 1998;95:8428-8430.
23. Hidalgo J, Penkowa M, Giralt M, Carrasco J, Molinero A. Metallothionein expression and oxidative stress in the brain. Methods Enzymol. 2002;348:238-249.
24. Okazaki Y, Miura N, Satoh M, Imura N, Naganuma A. Metallothionein- mediated resistance to multiple drugs can be induced by several anticancer drugs in mice. Biochem Biophys Res Commun. 1998;245:815-818.
25. Rizkalla KS, Cherian MG. Metallothionein: a potential marker for differentiating benign and neoplastic gastrointestinal lymphoid infiltrates. Pathology. 1997;29:141-146.
26. World Health Organization Classification of Tumours. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
27. Gronbaek K, de Nully BP, Moller MB, et al. Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma.Leukemia. 2000;14:1727-1735.
28. Gronbaek K, Worm J, Ralfkiaer E, et al. ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma. Blood. 2002;100:1430-1437.
29. Hermine O, Haioun C, Lepage E, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma: Groupe d'Etude des Lymphomes de l'Adulte(GELA). Blood. 1996;87:265-272.
30. Staudt LM. Gene expression profiling of lymphoid malignancies. Annu Rev Med. 2002;53:303-318.
31. Staudt LM. Molecular diagnosis of the hematologic cancers. N Engl J Med. 2003;348:1777-1785.
32. Wright G, Tan B, Rosenwald A, et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2003;100:9991-9996.
33. Wang GW, Klein JB, Kang YJ. Metallothionein inhibits doxorubicin-induced mitochondrial cytochrome c release and caspase-3 activation in cardiomyocytes. Pharmacol Exp Ther. 2001;298:461-468.
34. Merten KE, Feng W, Zhang L, et al. Modulation of cytochrome C oxidase-va is possibly involved in metallothionein protection from doxorubicin cardiotoxicity. J Pharmacol Exp Ther. 2005;315:1314-1319.
35. He T, Wei D, Fabris D, Fenselau C. Intracellular sequestration of anti-tumor drugs by metallothionein. Cell Mol Biol (Noisy-le-grand). 2000;46:383-392.
36. Wei D, Fabris D, Fenselau C. Covalent sequestration of phosphoramide mustard by metallothionein an in vitro study. Drug Metab Dispos. 1999;27:786-791.
37. Lecane PS, Karaman MW, Sirisawad M, et al. Motexafin gadolinium and zinc induce oxidative stressresponses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005;65:11676-11688.
38. Penkowa M, Carrasco J, Giralt M, Moos T, Hidalgo J. CNS wound healing is severely depressed in metallothionein I- and II-deficient mice. J Neurosci. 1999;19:2535-2545.
39. Penkowa M, Espejo C, Martinez-Caceres EM, et al. Altered inflammatory response and increased nerodegeneration in metallothionein I+II deficient mice during experimental autoimmune encephalo-mylitis. J Neuroimmunol. 2001;119:248-260.